Key Highlights

  • July 7 2026 agreement gives Evolus exclusive U.S. Rights to the Profhilo injectable for aesthetic and dermatology uses.
  • No upfront or milestone payments are required; Evolus will purchase the product under a transfer‑price model after FDA clearance.
  • The contract runs for fifteen years from first FDA approval, with optional five‑year extensions and mandatory purchase volumes starting in year four.

Evolus, Inc. (NASDAQ: EOLS) disclosed a licensing arrangement with Swiss partner IBSA Institut Biochimique SA on July 7 2026. The deal grants Evolus sole authority to develop, market and distribute the Profhilo injectable hyaluronic acid formulation across the United States for aesthetic and dermatological applications.

Exclusive Development Rights

Under the agreement, Evolus assumes full responsibility for U.S. Development, clinical testing and regulatory submissions needed to obtain FDA approval. The company will retain any resulting approval and associated documentation, positioning it as the sole holder of the product’s U.S.

Regulatory status.

Commercial Terms Without Upfront Fees

The partnership does not require Evolus to make any initial cash payments or meet milestone-based obligations to IBSA. After securing FDA clearance, Evolus will acquire Profhilo from IBSA according to a transfer‑price formula that may be adjusted periodically as outlined in the contract.

Minimum Purchase Obligations

The agreement imposes baseline purchasing commitments that begin in the fourth year following the commercial launch of the product. Failure to satisfy these thresholds could trigger a conversion of Evolus’s exclusive rights to non‑exclusive status or potentially lead to termination, subject to defined exceptions.

Long‑Term Duration and Renewal Options

The license extends for fifteen years from the date of the first FDA approval of Profhilo. The contract also provides for successive five‑year renewal periods, contingent upon compliance with the terms set forth in the agreement. Market.

This flexibility supports broader growth opportunities in the aesthetics and dermatology sectors.

Regulatory and Commercial Responsibilities

Evolus will bear all costs associated with U.S. Development, including clinical trials and regulatory filings. Upon successful FDA approval, the company will manage distribution and marketing activities, leveraging its existing infrastructure to support the new product launch.

Market Implications

The exclusive licensing structure, coupled with the absence of upfront payments, positions Evolus to potentially enhance its revenue stream while limiting immediate capital outlays. Investors will monitor the progress of FDA submissions and the company’s ability to meet the stipulated purchase minimums.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.